I CARE STUDY; Improving Care After colon canceR treatment in the Netherlands - Personalised care to Enhance quality of life

Recruiting

Conditions: curative
10017990
10017991
colon cancer

Registration Number: NL-OMON53014

Lead Sponsor: Academisch Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: Not specified

Target Recruitment: 300

Inclusion Criteria

•Carcinoma located in the colon and rectosigmoid defined as a tumour located 15
cm above the anal verge by coloscopy or above the sacral promontory as seen
preoperatively
•Stage 1, 2 and 3 carcinoma
•Surgical treatment with curative intent
•Qualified for routine follow-up attendance by surgeon according to the
national guideline.
•Patients with temporary stoma and who received adjuvant chemotherapy are also
eligible.

Exclusion Criteria

•Stage IV colorectal tumours
•Hereditary colorectal cancer
•Colorectal cancer in patients with inflammatory bowel disease
•Rectal cancer
•(Sub)total colectomy or proctocolectomy
•History of second primary cancer (except basal cell carcinoma of the skin)
within the last 15 years
•Participation in other (clinical) research, which will affect the outcome
measurements of this trial
•Permanent open wounds after surgery or other conditions where specialised care
is needed
•Any other condition that warrants increased intensity of surveillance with
respect to colon cancer follow-up
•Not able to speak Dutch or English

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Primary outcomes include quality of life and patient satisfaction. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Secondary outcomes include physical outcomes, psychosocial outcomes, number of<br /><br>investigations, referrals and related communication between secondary and<br /><br>primary care, (time of) recurrence detection and protocol adherence, attention<br /><br>to preventive care, cost effectiveness, and preference of care at the end of<br /><br>the trial.</p><br>